The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.
The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease — but not diabetes.
Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. The new study looked to see if the same was true in those who don't have that disease. The new study, paid for by the company, included more than 17,500 people in 41 countries. Participants were age 45 and older, had a body mass index of 27 or higher and were tracked for more than three years on average. They took typical drugs for their heart conditions, but they were also randomly assigned to receive weekly injections of Wegovy or a dummy shot.
Study volunteers who took Wegovy lost about 9% of their weight while the placebo group lost less than 1%. Still, "it remains unclear" how much of the results were a benefit of losing weight or the drug itself, an editorial accompanying the study noted. Wegovy is part of a new class of injectable medications for obesity. On Wednesday, the U.S. Food and Drug Administration approved Eli Lilly's Zepbound, a version of the diabetes drug Mounjaro, for weight control.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Obesity Drug Wegovy Cut Risk of Serious Heart Problems by 20%, Study FindsThe popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.The research is the first to document that an obesity medication can not only...
Read more »
Obesity drug Wegovy cut risk of serious heart problems by 20%, study findsA new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.
Read more »
Obesity drug Wegovy cut risk of heart problems by 20%, study findsIt's being praised as a landmark study that could change the way doctors treat heart disease in some patients.
Read more »
Weight-Loss Drug Wegovy Reduces Risk of Heart Problems by 20%The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.
Read more »
Why weight-loss drug Wegovy shows promise for heart diseaseBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Novo Nordisk's Weight-Loss Drug Wegovy Reduces Cardiovascular Risk in Non-Diabetic PatientsClosely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say
Read more »